Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | PDE6A | P16499 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 7/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1229435 | 0.79 | SCD (0.63) | SCD | |
| SCHEMBL1229476 | 0.79 | HRH1 (0.44) | SCD | |
| SCHEMBL1231593 | 0.78 | SCD (0.46) | SCD | |
| SCHEMBL1230359 | 0.78 | SCD (0.49) | SCD | |
| SCHEMBL1230984 | 0.78 | SCD (0.49) | SCD | |
| SCHEMBL1230300 | 0.78 | SCD (0.51) | SCD | |
| SCHEMBL12897967 | 0.78 | SCD (0.47) | SCD | |
| SCHEMBL1231190 | 0.77 | SCD (0.66) | SCD | |
| SCHEMBL1231046 | 0.77 | SCD (0.46) | SCD | |
| SCHEMBL1231224 | 0.77 | SCD (0.45) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462121-B1 | DERIVATIVES OF 2H PYRIDAZIN-3-ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PF MEDICAMENT (FR) | 2015-02-18 | — | — | EP | disclosed |
| EP-2462121-B1 | DERIVATIVES OF 2H PYRIDAZIN-3-ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PF MEDICAMENT (FR) | 2015-02-18 | — | — | EP | disclosed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| EP-2462121-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | Pierre Fabre Médicament (FR) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011015629-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011015629-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | SCD, SCD5, CYP2S1 | PDE5A 1445/4885PDE6A 3409/4885DPP4 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.